What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Niacin is a B-complex vitamin used as a lipid-altering drug since the 1950s. Niacin improves multiple lipid parameters. Atherosclerotic coronary heart disease outcome studies support niacin's efficacy in reducing coronary heart disease events, either as monotherapy or when used in combination with other lipid-altering drugs. The most commonly reported reason for the lack of its more widespread clinical use is niacin-induced flushing. RECENT FINDINGS: Laropiprant is a highly selective prostaglandin D2 receptor 1 antagonist that mitigates niacin-induced flushing. SUMMARY: This review examines the history and provides a perspective regarding the extended-release niacin/laropiprant development program, which was designed to better allow patients to achieve a more therapeutic niacin dose of 2 g/day, without the need for titration. Ongoing coronary heart disease outcome studies will provide better insight as to the benefits of niacin in general, and the safety and efficacy of extended-release niacin/laropiprant specifically.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“today, more effective and well-tolerated drugs are available [[209], [210], [211]].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [209]
In the citing paper
“the first hypercholesterolemia drugs were poorly tolerated or had adverse side effects”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [209]
Citations
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Blankenhorn, D. H. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390230069027 · Cited by 1,655
Kane, J. P. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450230043027 · Cited by 829
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Diabetes Care · doi:10.2337/dc08-9018 · Cited by 707
Carlson, L. A., & ROSENHAMER, G. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15891.x · Cited by 677
Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review
CARLSON, L. A. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01528.x · Cited by 581
Cited by
Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management
Chehade, J. M., Gladysz, M., & Mooradian, A. D. (2013) · Drugs · doi:10.1007/s40265-013-0023-5 · Cited by 290
Hanson, J., Gille, A., Zwykiel, S., Lukasova, M., Clausen, B. E., Ahmed, K., Tunaru, S., Wirth, A., & Offermanns, S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42273 · Cited by 197
Pharmacological strategies for lowering LDL cholesterol: statins and beyond
Brautbar, A., & Ballantyne, C. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.2 · Cited by 134
Self-citationLauring, B., Taggart, A. K. P., Tata, J. R., Dunbar, R., Caro, L., Cheng, K., Chin, J., Colletti, S. L., Cote, J., Khalilieh, S., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003877 · Cited by 126
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83
Self-citationBays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Self-citationBays, H. E., Kothari, S. N., Azagury, D. E., Morton, J. M., Nguyen, N. T., Jones, P. H., Jacobson, T. A., Cohen, D. E., Orringer, C. E., Westman, E. C., et al. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.01.007 · Cited by 61
Self-citationProstanoids receptors signaling in different diseases/cancers progression
Yang, Y., Tang, L., & Wei, W. (2013) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2012.752003 · Cited by 27
Nicotinic acid: clinical considerations
Kei, A. A., & Elisaf, M. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.682981 · Cited by 23
Lebouché, B., Jenabian, M.-A., Singer, J., Graziani, G. M., Engler, K., Trottier, B., Thomas, R., Brouillette, M., & Routy, J. (2014) · Trials · doi:10.1186/1745-6215-15-390 · Cited by 17
Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
Bays, H. E. (2014) · International Journal of General Medicine · doi:10.2147/ijgm.s65148 · Cited by 16
Self-citationBays, H. E., Shah, A. K., Lin, J., Sisk, C. M., Dong, Q., & Maccubbin, D. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11631530-000000000-00000 · Cited by 16
Self-citationExtended-release niacin/laropiprant lipid-altering consistency across patient subgroups
Bays, H. E., Shah, A. K., Dong, Q., Sisk, C. M., & Maccubbin, D. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02620.x · Cited by 15
Self-citationSafety review of combination drugs for hyperlipidemia
Farnier, M. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.540237 · Cited by 15
Hypertriglyceridaemia, Postprandial Lipaemia and Non-HDL Cholesterol
Stefanutti, C., Labbadia, G., & Athyros, V. G. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140620120130 · Cited by 15
Bays, H. E., Giezek, H., McKenney, J. M., O’Neill, E. A., & Tershakovec, A. M. (2012) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0005 · Cited by 14
Self-citationMitchel, Y., Bays, H. E., Brinton, E. A., Triscari, J. M., Chen, E., Maccubbin, D., MacLean, A. A., Gibson, K., Ruck, R. A., Johnson‐Levonas, A. O., et al. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s70907 · Cited by 12
Self-citationLipid lowering therapy in type 2 diabetes
Föger, B. (2011) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-011-0908-4 · Cited by 11
Nicholls, & Hussein (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s7306 · Cited by 11
Pharmacotherapy of dyslipidemias in the adult population
Vigna, G. B., & Fellin, R. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.513116 · Cited by 9
Bays, H. E., Maki, K. C., & Schmitz, K. (2010) · Endocrine Practice · doi:10.4158/ep10251.or · Cited by 9
Self-citationSiddiqui, R. A., VanHorn, Altenburg, Harvey, Xu, Kovács, & Siddiqui, R. A. (2012) · Journal of Inflammation Research · doi:10.2147/jir.s29044 · Cited by 9
Brinton, E. A., Kashyap, M. L., Vo, A. N., Thakkar, R. B., Jiang, P. X., & Padley, R. J. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11592560-000000000-00000 · Cited by 6
The Bile Acid Sequestrant Acceptability Scale validation study
Bays, H. E., Maki, K. C., & Schmitz, K. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02467.x · Cited by 4
Self-citationRodríguez, A., & Kwiterovich, P. O. (2011) · Springer eBooks · doi:10.1007/978-3-642-15720-2_32 · Cited by 3
Drugs in development for management of lipoprotein disorders
Brown, W. V., Bays, H. E., Davidson, M. H., & Goldberg, A. C. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.01.004 · Cited by 2
Self-citationClinical implications of the BARI 2D and COURAGE trials of coronary artery disease
Kuller, L. H. (2010) · Coronary Artery Disease · doi:10.1097/mca.0b013e32833bfdcd · Cited by 2
Are add-on agents to statin therapy necessary in hypercholesterolemia?
Dayer-Berenson, L., Finckenor, M., & Tuzzolino, M. (2014) · Clinical Lipidology · doi:10.2217/clp.14.57 · Cited by 1
Brown, W. V., Bays, H. E., Maki, K. C., & Wild, R. A. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.10.001
Self-citation
Metadata
- Authors
- Bays, H. E., & Ballantyne, C.
- Affiliations
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Baylor College of Medicine (US)
- Corresponding author
- Bays, Harold E
- Venue
- Current Opinion in Lipidology
- Published
- 2009-12
- Volume
- 20
- Issue
- 6
- Pages
- 467-476
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W2068615855
- Cited by
- 29
- References
- 42
- Citations by year
- 2022: 1 · 2016: 1 · 2015: 1 · 2014: 4 · 2013: 2 · 2012: 7
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- nicotinic acid, laropiprant, lipid-lowering therapy, coronary artery disease, hypercholesterolemia, drug development, dose titration
- MeSH terms
- Hypolipidemic Agents, Coronary Disease, Delayed-Action Preparations, Drug Combinations, Flushing, Humans, Indoles, Lipids, Niacin, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.